Andrew Singleton

<table class="infobox infobox-researcher">
<tr>
<th class="infobox-header" colspan="2">Andrew Singleton</th>
</tr>
<tr>
<td class="infobox-image" colspan="2">
<em>Photo placeholder</em>
</td>
</tr>
<tr>
<td class="label">Affiliations</td>
<td>NIH<br>University College London</td>
</tr>
<tr>
<td class="label">Country</td>
<td>USA/UK</td>
</tr>
<tr>
<td class="label">H-index</td>
<td>200+</td>
</tr>
<tr>
<td class="label">ORCID</td>
<td><a href="https://orcid.org/0000-0002-8656-8853" target="_blank">0000-0002-8656-8853</a></td>
</tr>
<tr>
<td class="label">Research Focus</td>
<td><a href="/diseases/parkinsons-disease">Parkinson's Disease</a>, <a href="/diseases/alzheimers">Alzheimer's Disease</a>, <a href="/diseases/ftd">FTD</a></td>
</tr>
<tr>
<td class="label">Mechanisms</td>
<td><a href="/mechanisms/alpha-synuclein">Alpha-synuclein</a>, <a href="/mechanisms/familial-parkinsons-genetics">Genetics</a>, <a href="/mechanisms/protein-aggregation">Protein aggregation</a></td>
</tr>
</table>

Andrew Singleton

Overview

<table class="infobox infobox-researcher">
<tr>
<th class="infobox-header" colspan="2">Andrew Singleton</th>
</tr>
<tr>
<td class="infobox-image" colspan="2">
<em>Photo placeholder</em>
</td>
</tr>
<tr>
<td class="label">Affiliations</td>
<td>NIH<br>University College London</td>
</tr>
<tr>
<td class="label">Country</td>
<td>USA/UK</td>
</tr>
<tr>
<td class="label">H-index</td>
<td>200+</td>
</tr>
<tr>
<td class="label">ORCID</td>
<td><a href="https://orcid.org/0000-0002-8656-8853" target="_blank">0000-0002-8656-8853</a></td>
</tr>
<tr>
<td class="label">Research Focus</td>
<td><a href="/diseases/parkinsons-disease">Parkinson's Disease</a>, <a href="/diseases/alzheimers">Alzheimer's Disease</a>, <a href="/diseases/ftd">FTD</a></td>
</tr>
<tr>
<td class="label">Mechanisms</td>
<td><a href="/mechanisms/alpha-synuclein">Alpha-synuclein</a>, <a href="/mechanisms/familial-parkinsons-genetics">Genetics</a>, <a href="/mechanisms/protein-aggregation">Protein aggregation</a></td>
</tr>
</table>

Andrew Singleton

Overview

Andrew Singleton is a renowned neuroscientist and geneticist whose research has fundamentally shaped our understanding of the genetics and molecular mechanisms underlying neurodegenerative diseases, particularly Parkinson's disease. His work at the intersection of genetic discovery and mechanistic biology has been instrumental in identifying several key genes involved in neurodegeneration. As a senior investigator at the National Institute on Aging and professor at University College London, Singleton has led groundbreaking studies that have transformed our understanding of Parkinson's disease pathogenesis and opened new avenues for therapeutic development. [@singleton1997; @singleton2003; @hernandez2019]

Singleton's contributions span the full spectrum of neurodegenerative disease research, from gene discovery through mechanistic studies to translational applications. His discovery that alpha-synuclein gene duplication causes familial Parkinson's disease provided the first direct evidence that increased expression of this protein is sufficient to cause neurodegeneration, establishing alpha-synuclein as a central therapeutic target. This landmark finding transformed the field and continues to guide drug development efforts more than two decades later. [@singleton2003; @xu2015]

Key Discoveries

Alpha-Synuclein (SNCA)

Singleton's group was among the first to demonstrate that multiplication of the [SNCA](/genes/snca) gene causes familial Parkinson's disease. This groundbreaking finding established that increased expression of alpha-synuclein is sufficient to cause parkinsonism, providing direct evidence for the pathological role of this protein in PD pathogenesis. The discovery published in Science in 2003 represented a paradigm shift in understanding PD etiology and established the field's focus on protein aggregation mechanisms. [@singleton2003; @xu2015]

This discovery catalyzed the field's focus on alpha-synuclein aggregation and led to:

• Understanding of Lewy body pathology: The identification of SNCA multiplication as causative established that alpha-synuclein aggregation is not merely a pathological hallmark but a primary driver of neurodegeneration. This reframed Lewy bodies from incidental findings to pathogenic entities worthy of therapeutic targeting. [@chu2016]
• Development of alpha-synuclein-targeted therapeutics: The genetic evidence from Singleton's work provided the scientific foundation for antibody therapies (BIIB122/BTK-88), small molecule aggregation inhibitors (buntanetap), and antisense oligonucleotides targeting SNCA mRNA. Clinical trials of these agents continue to be guided by the mechanistic insights from his discoveries. [@simuni2016; @masliah2015]
• Biomarker development based on alpha-synuclein: The understanding that alpha-synuclein burden correlates with disease severity enabled development of CSF and blood-based biomarkers including alpha-synuclein seeds in real-time quaking-induced conversion (RT-QuIC) assays

LRRK2 Discovery

Singleton's research contributed significantly to the identification and characterization of [LRRK2](/genes/lrrk2) (leucine-rich repeat kinase 2) mutations as a major cause of familial Parkinson's disease. LRRK2 is now recognized as the most common genetic cause of PD, with over 100 pathogenic mutations identified. His work characterized the spectrum of LRRK2 variants ranging from highly penetrant mutations causing autosomal dominant PD to common risk variants contributing to sporadic disease. [@williams2015; @freund2013]

The LRRK2 discoveries have had major therapeutic implications:

• Kinase inhibitor development: The establishment of LRRK2 as a pathogenic driver enabled development of LRRK2 kinase inhibitors now in clinical trials (DNL151/BIIB122)
• Genetic risk stratification: LRRK2 variants are now incorporated into genetic counseling for at-risk individuals
• Understanding of common vs. rare variant contributions: Singleton's GWAS work distinguished between common risk alleles and rare causative variants

Parkinson's Disease Genetics

Beyond SNCA and LRRK2, Singleton has contributed to identifying numerous genetic determinants of Parkinson's disease:

• [GBA](/genes/gba) mutations as a significant PD risk factor: His group demonstrated that heterozygous GBA mutations increase PD risk 5-10 fold, establishing the link between Gaucher disease and PD that has led to substrate reduction therapy approaches. This discovery also highlighted lysosomal dysfunction as a key disease mechanism. [@blumenstock2017]
• [VPS35](/genes/vps35) mutations causing familial PD: The identification of the D620N VPS35 mutation provided evidence for retromer dysfunction in PD pathogenesis and opened new therapeutic targets.
• Numerous risk loci through genome-wide association studies: Singleton has led or contributed to multiple large-scale GWAS meta-analyses identifying over 90 loci contributing to sporadic PD risk. These studies have revealed new biological pathways and therapeutic targets. [@pankratz2009; @nalls2014; @hernandez2019]
• PARK loci systematic characterization: His systematic evaluation of the PARK nomenclature has clarified the genetic landscape of familial PD

Career and Academic Positions

National Institute on Aging

As a Senior Investigator at the [NIH](/institutions/nih) National Institute on Aging, Singleton leads the Laboratory of Neurogenetics within the Translational Gerontology Branch. This position enables him to pursue large-scale genetic studies while maintaining active collaborations with basic scientists investigating mechanism. The NIA laboratory provides access to extensive patient cohorts and enables integration of genetic findings with clinical and pathological characterization.

University College London

Singleton holds a professorial position at [University College London](/institutions/university-college-london) where he maintains active collaborations with European researchers. The UCL position facilitates engagement with the substantial European PD patient populations and enables Singleton's group to participate in continent-wide genetic studies.

Training Background

Singleton received his doctoral training in human genetics with emphasis on neurodegenerative disease genetics. His background bridges clinical genetics and molecular neuroscience, enabling translational research connecting genetic discoveries to biological mechanisms.

Research Focus

Disease Areas

Singleton's research spans multiple neurodegenerative diseases with emphasis on:

• [Parkinson's Disease](/diseases/parkinsons-disease): The primary focus of his research program, encompassing genetic, mechanistic, and therapeutic aspects
• [Alzheimer's Disease](/diseases/alzheimers-disease): Investigation of shared genetic risk factors and mechanistic overlaps with PD
• [Frontotemporal Dementia](/diseases/frontotemporal-dementia): Studies of genetic determinants of FTD and relationship to other neurodegenerative diseases
• [Dementia with Lewy Bodies](/diseases/lewy-body-dementia): Characterization of genetic factors influencing DLB phenotype

Mechanisms of Interest

• [Alpha-synuclein](/mechanisms/alpha-synuclein) pathology and aggregation: The primary focus of his mechanistic studies, from protein biochemistry to therapeutic targeting
• [Protein aggregation](/mechanisms/protein-aggregation): Broader investigation of aggregation-prone proteins in neurodegeneration including tau, TDP-43, and dipeptide repeat proteins
• Genetic determinants of neurodegeneration: Systematic gene discovery and functional characterization
• Kinase signaling pathways ([LRRK2](/genes/lrrk2)): Understanding LRRK2 biology and developing kinase inhibitors

Methodological Approach

Singleton's research integrates multiple methodological approaches:

• Genetic linkage analysis and GWAS: Large-scale studies identifying genetic variants contributing to disease risk
• Functional genomics in model systems: Characterization of variant effects using cell biological and animal models
• Stem cell models of neurodegeneration: Induced pluripotent stem cell (iPSC) derived neurons carrying patient mutations
• Translational research connecting genetic findings to therapy: Working with pharmaceutical partners to develop genetically-informed therapeutics

Major Scientific Contributions

Discovery of SNCA Locus Triplication

The 2003 Science publication demonstrating that SNCA locus triplication causes familial PD remains one of the most influential papers in Parkinson's disease research. This work established the dose-dependency of alpha-synuclein toxicity and provided the genetic foundation for all subsequent alpha-synuclein targeting therapies. The discovery has been cited thousands of times and continues to guide clinical trial design. [@singleton2003]

Establishment of Large-Scale GWAS Consortiums

Singleton has been instrumental in establishing and leading large international consortia for PD genetics. The Genetic Initiative for Parkinson's Disease (GIOPD) and subsequent meta-analyses have identified over 90 genetic risk loci for PD. These studies have revealed novel biological pathways including autophagy-lysosome function, synaptic biology, and neuroinflammation. [@nalls2014; @hernandez2019]

Genetic Architecture of LRRK2

Detailed characterization of LRRK2 variation in PD populations has established this gene as the most common genetic cause of familial PD. Singleton's work has characterized the spectrum of pathogenic variants, established genotype-phenotype correlations, and enabled clinical genetic testing for LRRK2-associated PD. [@satake2010; @williams2015]

GBA-PD Connection

The identification of GBA mutations as a major PD risk factor represented a paradigm-shifting discovery linking lysosomal storage disorders to neurodegenerative disease. This finding has had substantial clinical implications, influencing genetic counseling, clinical trial enrichment, and therapeutic development. [@blumenstock2017]

Major Publications

Singleton has authored over 500 publications, with major contributions including:

Collaborations and Research Network

International consortia

Singleton's research benefits from extensive international collaborations:

• International Parkinson's Disease Genetics Consortium (IPDGC): Founding member and active participant in this global network coordinating genetic studies
• Michael J. Fox Foundation Parkinson's Progression Markers Initiative (PPMI): Genetic characterization of PPMI cohorts
• Genome Technology Center for Neurodegeneration: Multi-institutional resource for genetic studies

Industry Partnerships

Singleton maintains active collaborations with pharmaceutical companies developing neurodegenerative disease therapeutics:

• Biogen: Genetic validation of therapeutic targets
• Denali Therapeutics: LRRK2 inhibitor development using genetic insights
• Genentech/Roche: Alpha-synuclein antibody development

Awards and Recognition

Singleton's contributions have been recognized through numerous awards:

• NIH Director's Award: Recognition for outstanding contributions to understanding Parkinson's disease genetics
• American Academy of Neurology Award: Contributions to movement disorders research
• Parkinson's Disease Foundation Award: Recognition for advancing understanding of PD
• Inaugural Lewy Body Dementia Award: Contributions to understanding DLB genetics

Recent Research (2024-2026)

Genetic Studies

Recent work has focused on:

• Rare variant discovery: Whole genome sequencing of large PD cohorts to identify rare causative variants
• Polygenic risk scores: Development of comprehensive polygenic risk scores integrating common and rare variant information
• Ancestral diversity: Expansion of genetic studies to underrepresented populations

Functional Studies

• Alpha-synuclein mechanisms: Ongoing studies of how SNCA variants affect protein aggregation and cellular toxicity
• LRRK2 biology: Characterization of how pathogenic LRRK2 variants affect kinase activity and neuronal function
• Lysosomal dysfunction: Studies linking GBA variants to lysosomal impairment in PD pathogenesis

Therapeutic Translation

• Genetic stratification for clinical trials: Development of genetic criteria for patient stratification in therapeutic trials
• Target validation: Functional studies validating genetic findings as therapeutic targets
• Biomarker development: Integration of genetic information with biomarker development for clinical trials

Institutional Context

Primary institutional affiliations:

• [NIH](/institutions/nih) — National Institute on Aging, USA
• [University College London](/institutions/university-college-london) — UK

External Links

• ORCID: [https://orcid.org/0000-0002-8656-8853](https://orcid.org/0000-0002-8656-8853)
• Google Scholar: [Search for Andrew Singleton](https://scholar.google.com/scholar?q=author%3A%22Andrew+Singleton%22)
• PubMed: [Author search for Andrew Singleton](https://pubmed.ncbi.nlm.nih.gov/?term=Andrew+Singleton%5BAuthor%5D)
• NIH Profile: [Laboratory of Neurogenetics](https://www.nia.nih.gov/research/labs/laboratory-neurogenetics)

See Also

• [Researchers and Institutions Index](/researchers)
• [Diseases Index](/diseases)
• [Mechanisms Index](/mechanisms)
• [Alpha-Synuclein](/proteins/alpha-synuclein)
• [LRRK2 Gene](/genes/lrrk2)
• [Parkinson's Disease Genetics](/mechanisms/familial-parkinsons-genetics)
• [NIH](/institutions/nih)
• [University College London](/institutions/university-college-london)

References